Truist lowered the firm’s price target on Regeneron (REGN) to $1,126 from $1,137 and keeps a Buy rating on the shares after its Q3 results. Investor focus has been on Eylea and Eylea HD ...

Regeneron Pharmaceuticals ( (REGN)) has released its Q3 earnings. Here is a breakdown of the information Regeneron Pharmaceuticals presented to its investors. Regeneron Pharmaceuticals, Inc. is a ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report third-quarter results on Oct. 31, 2024. The Zacks Consensus Estimate for revenues is pegged at $3.67 billion, while the same ...

With U.S. sales of $392 million in the third quarter, Regeneron’s high-dose version of Eylea is closing in on blockbuster sales in its first full year on the market. The bad news for the company ...

Shares of Regeneron (NASDAQ:REGN) lost nearly a third of their value since my previous update where I said that the stock is near the high end of the valuation range that I deemed appropriate to ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $1,184.00. Terence Flynn’s rating is ...

Regeneron has steadily grown into a massive presence in the Albany region, shaping everything from real estate to workforce. And now it's expanding into Albany and Saratoga counties. Two billion ...

Shares of REGN opened at $843.60 on Friday. Regeneron Pharmaceuticals has a twelve month low of $783.57 and a twelve month high of $1,211.20. The stock has a market cap of $93.00 billion, a PE ...

Despite a beat on both top and bottom lines with its Q3 2024 financials, Regeneron Pharmaceuticals (NASDAQ:REGN) lost more than 10% on Thursday, a move BMO Capital Markets attributed to lower-than ...

Barclays lowered the firm’s price target on Regeneron (REGN) to $1,065 from $1,080 and keeps an Overweight rating on the shares post the Q3 report. The firm says recent pressure on Regeneron ...